STROKOG (stroke and cognition consortium): An international consortium to examine the epidemiology, diagnosis, and treatment of neurocognitive disorders in relation to cerebrovascular disease

Perminder S. Sachdev* (Corresponding Author), Jessica W. Lo, John D. Crawford, Lisa Mellon, Anna Hickey, David Williams, Regis Bordet, Anne-Marie Mendyk, Patrick Gele, Dominique Deplanque, Hee-Joon Bae, Jae-Sung Lim, Amy Brodtmann, Emilio Werden, Toby Cumming, Sebastian Kohler, Frans R. J. Verhey, Yan-Hong Dong, Hui Hui Tan, Christopher ChenXu Xin, Raj N. Kalaria, Louise M. Allan, Rufus O. Akinyemi, Adesola Ogunniyi, Aleksandra Klimkowicz-Mrowiec, Martin Dichgans, Frank A. Wollenweber, Vera Zietemann, Michael Hoffmann, David W. Desmond, Thomas Linden, Christian Blomstrand, Bjorn Fagerberg, Ingmar Skoog, Olivier Godefroy, Melanie Barbay, Martine Roussel, Byung-Chul Lee, Kyung-Ho Yu, Joanna Wardlaw, Stephen J. Makin, Fergus N. Doubal, Francesca M. Chappell, Velandai K. Srikanth, Amanda G. Thrift, Geoffrey A. Donnan, Nagaendran Kandiah, Russell J. Chander, Xuling Lin, Charlotte Cordonnier, Solene Moulin, Costanza Rossi, Behnam Sabayan, David J. Stott, J. Wouter Jukema, Susanna Melkas, Hanna Jokinen, Timo Erkinjuntti, Vincent C. T. Mok, Adrian Wong, Bonnie Y. K. Lam, Didier Leys, Hilde Henon, Stephanie Bombois, Darren M. Lipnicki, Nicole A. Kochan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

47 Citations (Scopus)
6 Downloads (Pure)


INTRODUCTION: The Stroke and Cognition consortium (STROKOG) aims to facilitate a better understanding of the determinants of vascular contributions to cognitive disorders and help improve the diagnosis and treatment of vascular cognitive disorders (VCD). METHODS: Longitudinal studies with >/=75 participants who had suffered or were at risk of stroke or TIA and which evaluated cognitive function were invited to join STROKOG. The consortium will facilitate projects investigating rates and patterns of cognitive decline, risk factors for VCD, and biomarkers of vascular dementia. RESULTS: Currently, STROKOG includes 25 (21 published) studies, with 12,092 participants from five continents. The duration of follow-up ranges from 3 months to 21 years. DISCUSSION: Although data harmonization will be a key challenge, STROKOG is in a unique position to reuse and combine international cohort data and fully explore patient level characteristics and outcomes. STROKOG could potentially transform our understanding of VCD and have a worldwide impact on promoting better vascular cognitive outcomes.
Original languageEnglish
Pages (from-to)11-23
Number of pages13
JournalAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Early online date18 Nov 2016
Publication statusPublished - 2017

Bibliographical note

ASPIRE‐S: The authors acknowledge the ASPIRE‐S Steering Group members: Professor Hannah McGee, Royal College of Surgeons in Ireland; Professor Emer Shelley, Royal College of Surgeons in Ireland; Professor Peter Kelly, Mater Misericordiae University Hospital, Dublin; Dr Eamon Dolan, Connolly Hospital, Dublin. BIOSTROKE and STROKDEM: French Health Ministery, the Vascog FHU, the ‘Fondation Coeur et Artères’. CANVAS: CANVAS researchers wish to acknowledge support from the NHMRC (APP1020526 and APP1094974), Sidney and Fiona Myer Foundation and the Collie Trust. CASPER: The CASPER project team consists of Ms. Syenna Schievink, Ms Elles Douven, Dr Sebastian Köhler, Dr Pauline Aalten, Dr Julie Staals, Professor Robert van Oostenbrugge, and Professor Frans Verhey. COAST: The authors thank all participants for their involvement, the research team from NUHS Memory Ageing and Cognition Centre for data collection. CogFAST‐UK: The authors are very grateful to the patients, families, clinical staff and previous co‐investigators for their co‐operation and help with the execution of the study. CogFAST‐Nigeria: The authors are very grateful to the patients, families and clinical staff for their co‐operation and help with the execution of the study. DSDB: The Durban Cerebrovascular Group, Department of Surgery and Neurology, University of Kwa‐Zulu Natal and Entabeni Hospital Stroke Center, Durban, South Africa. GRECOG‐VASC: French Health Ministry. MSS‐II: MMS2 acknowledges the Wellcome Trust, Row Fogo Charitable Trust; Fergus Doubal is supported by the Stroke Association and Garfield Weston Foundation. NEMESIS: The National Health and Medical Research Council of Australia (NHMRC). PITCH: Charlotte Cordonnier is a member of the Institut Universitaire de France.

: R.N.K. was supported
by grants from the Newcastle Centre for Brain Ageing
and Vitality (BBSRC, EPSRC, ESRC and MRC, LLHW;
G0700718). The original CogFAST-UK research programmes were supported by the UK Medical Research
Council (MRC, G0500247 and G9817621). CogFASTNigeria: R.O.A. was supported by a fellowship from the International Brain Research Organization (IBRO) Paris,
France and by an ORS Award from the Newcastle University, UK. DEDEMAS: Vascular Dementia Research Foundation. Flutemetamol (18F) was provided by GE
Healthcare. Epi USA: National Institutes of Health (grants
R01-NS26179 and P01-AG07232). GRECOG-VASC:
French Health Ministry. MSS-II: Wellcome Trust number
WT088134/Z/09/A.Row Fogo Trust.

NHMRC. Grant Numbers: APP1020526, APP1094974
Sidney and Fiona Myer Foundation
Collie Trust
Stroke Association and Garfield Weston Foundation


  • Cohort studies
  • Vascular dementia
  • Post-stroke dementia
  • Vascular cognitive disorder
  • Small vessel disease
  • Data harmonization
  • International consortium


Dive into the research topics of 'STROKOG (stroke and cognition consortium): An international consortium to examine the epidemiology, diagnosis, and treatment of neurocognitive disorders in relation to cerebrovascular disease'. Together they form a unique fingerprint.

Cite this